Found: 24
Select item for more details and to access through your institution.
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 401, doi. 10.1038/nrd3705
- By:
- Publication type:
- Article
Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration.
- Published in:
- Journal of Bone & Mineral Research, 2006, v. 21, n. 10, p. 1571, doi. 10.1359/jbmr.060706
- By:
- Publication type:
- Article
In Vivo RANK Signaling Blockade Using the Receptor Activator of NF-κB:Fc Effectively Prevents and Ameliorates Wear Debris-Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis.
- Published in:
- Journal of Bone & Mineral Research, 2002, v. 17, n. 2, p. 192, doi. 10.1359/jbmr.2002.17.2.192
- By:
- Publication type:
- Article
Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis.
- Published in:
- Stem Cells, 2013, v. 31, n. 9, p. 1954, doi. 10.1002/stem.1454
- By:
- Publication type:
- Article
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
- Published in:
- Annals of the New York Academy of Sciences, 2012, v. 1263, n. 1, p. 29, doi. 10.1111/j.1749-6632.2012.06674.x
- By:
- Publication type:
- Article
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.
- Published in:
- PLoS ONE, 2015, v. 10, n. 6, p. 1, doi. 10.1371/journal.pone.0128467
- By:
- Publication type:
- Article
Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy.
- Published in:
- Journal of Cellular Biochemistry, 1993, v. 53, n. 1, p. 61, doi. 10.1002/jcb.240530108
- By:
- Publication type:
- Article
Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation.
- Published in:
- Stem Cells, 2016, v. 34, n. 4, p. 1027, doi. 10.1002/stem.2271
- By:
- Publication type:
- Article
Correlation of RANK and RANKL with mammographic density in primary breast cancer patients.
- Published in:
- Archives of Gynecology & Obstetrics, 2024, v. 310, n. 2, p. 1223, doi. 10.1007/s00404-024-07495-1
- By:
- Publication type:
- Article
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
- Published in:
- Nature, 2010, v. 468, n. 7320, p. 103, doi. 10.1038/nature09495
- By:
- Publication type:
- Article
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
- Published in:
- Immunological Reviews, 2017, v. 276, n. 1, p. 112, doi. 10.1111/imr.12518
- By:
- Publication type:
- Article
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
- Published in:
- Breast Cancer Research, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13058-015-0538-7
- By:
- Publication type:
- Article
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.
- Published in:
- Breast Cancer Research, 2013, v. 15, n. 4, p. 1, doi. 10.1186/bcr3456
- By:
- Publication type:
- Article
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.
- Published in:
- 2013
- By:
- Publication type:
- journal article
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
- Published in:
- 2018
- By:
- Publication type:
- journal article
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
- Published in:
- Prostate, 2008, v. 68, n. 1, p. 92, doi. 10.1002/pros.20678
- By:
- Publication type:
- Article
Association of Signaling Proteins with a Nonmitogenic Heterodimeric Complex Composed of Epidermal Growth Factor Receptor and Kinase-Inactive p185<sup>c- neu</sup>".
- Published in:
- DNA & Cell Biology, 1996, v. 15, n. 1, p. 31, doi. 10.1089/dna.1996.15.31
- By:
- Publication type:
- Article
Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity.
- Published in:
- Clinical & Translational Immunology, 2019, v. 8, n. 10, p. N.PAG, doi. 10.1002/cti2.1081
- By:
- Publication type:
- Article
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
- Published in:
- Trials, 2019, v. 20, p. 1, doi. 10.1186/s13063-019-3951-x
- By:
- Publication type:
- Article
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
- Published in:
- 2019
- By:
- Publication type:
- journal article
The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor‐infiltrating T cells.
- Published in:
- Immunology & Cell Biology, 2019, v. 97, n. 2, p. 152, doi. 10.1111/imcb.12205
- By:
- Publication type:
- Article
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone
- Published in:
- Journal of Orthopaedic Research, 2005, v. 23, n. 6, p. 1475, doi. 10.1016/j.orthres.2005.05.004.1100230634
- By:
- Publication type:
- Article
Effects of receptor activator of NFκB (RANK) signaling blockade on fracture healing
- Published in:
- Journal of Orthopaedic Research, 2003, v. 21, n. 4, p. 676, doi. 10.1016/S0736-0266(03)00011-1
- By:
- Publication type:
- Article